A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM.
Witzig TE, et al. Among authors: ansell sm.
Leukemia. 2011 Feb;25(2):341-7. doi: 10.1038/leu.2010.226. Epub 2010 Dec 7.
Leukemia. 2011.
PMID: 21135857
Free PMC article.
Clinical Trial.